Clinical trial
A Study Evaluated the Safety and Efficacy of BAT6026 in Patients With Moderate to Severe Atopic Dermatitis Phase I/II Clinical Study
NCT06094179 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study Evaluated the Safety and Efficacy of BAT6026 in Patients With Moderate to Severe Atopic Dermatitis Phase I/II Clinical Study
- Lead sponsor
- Bio-Thera Solutions
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- November 9, 2023
- Completion date
- December 31, 2026
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.